Solventum Receives FDA Clearance for Combined Restrata and V.A.C. Wound Care Therapy

Key Facts

1Solventum received FDA 510(k) clearance for the combined use of Restrata Synthetic Electrospun Fiber Matrix and V.A.C. Therapy.

Solventum received FDA 510(k) clearance for the combined use of its Restrata Synthetic Electrospun Fiber Matrix and V.A.C. Therapy system. PR Newswire reported that the clearance allows the company to pair these two advanced technologies to create a streamlined path for active wound healing and optimize patient outcomes.

SOLV closed at $85.81 on October 16, 2026, with the stock reaching a day high of $89 and a low of $85.18 during the session. This regulatory milestone follows the company's efforts to integrate advanced technologies into its wound care portfolio, potentially strengthening its market position in the medical device sector.